Patent application number | Description | Published |
20090035868 | RAPID PROTEIN LABELING AND ANALYSIS - The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein. Following the labeling step, the proteins within the mixture can be separated and analyzed. In a further embodiment, a tag binding fluorogenic reagent that can bind to a tag on a tagged protein is added to specifically label the protein of interest. | 02-05-2009 |
20110014710 | COMPOSITIONS, METHODS AND KITS FOR BIARSENICAL FLUOROPHORE LABELING - Methods, compositions, and kits for labeling tetracysteine-tagged proteins with biarsenical fluorophores with increased specificity, including compositions, methods and kits particularly adapted for labeling of tetracysteine-tagged proteins to be resolved within an electrophoresis gel. | 01-20-2011 |
20110053205 | Composition and Methods for Expressing Reporter Molecules in Mammalian Cells - Disclosed herein is a novel system and methods for expressing exogenous genes, such as genes encoding fluorescent proteins, in mammalian cells. In one embodiment of this system and methods, a gene essential for viral infectivity or replication in cell culture is deleted or inactivated in the genome of a non-mammalian DNA virus. The exogenous gene operably linked to a mammalian promoter is then inserted into the non-replicative non-mammalian DNA virus. The non-replicative virus is propagated in a host cell that expresses in trans the deleted or inactivated gene or a functional homolog. | 03-03-2011 |
20110263001 | Compositions and Methods for Engineering Cells - The disclosure relates generally to genetic manipulation of stem and primary cells and to reprogramming of somatic cells, more specifically, human cells. In particular, compositions and methods are disclosed for the generation and maintenance of such engineered cells. | 10-27-2011 |
20130040304 | Compositions and Methods for Engineering Cells - The disclosure relates generally to genetic manipulation of stem and primary cells and to reprogramming of somatic cells, more specifically, human cells. In particular, compositions and methods are disclosed for the generation and maintenance of such engineered cells. | 02-14-2013 |
20140234979 | Rapid Protein Labeling and Analysis - The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein. Following the labeling step, the proteins within the mixture can be separated and analyzed. In a further embodiment, a tag binding fluorogenic reagent that can bind to a tag on a tagged protein is added to specifically label the protein of interest. | 08-21-2014 |
20160054327 | RAPID PROTEIN LABELING AND ANALYSIS - The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein. Following the labeling step, the proteins within the mixture can be separated and analyzed. In a further embodiment, a tag binding fluorogenic reagent that can bind to a tag on a tagged protein is added to specifically label the protein of interest. | 02-25-2016 |
Patent application number | Description | Published |
20090166922 | Mold Rotator - A mold rotator with a first section and a second section that are engaged approximately perpendicularly to each other to produce a base and an L-shaped platform for receiving the article. The base of the article rotator may have a curved section at the intersection of the first section and the second section and the article rotator may rotate on its curved section between a first position wherein the article rotator is supported on its first section and a second position wherein the article rotator is supported on its second section. Further, the article rotator allows an article to be safely rotated simply by lowering the article onto the article rotator so that the article rotator automatically rotates approximately 90° from a first position and a second, rotated position. The article rotator may include a stabilizing system wherein the article rotator can be stabilized at both a first position and second position which is approximately 90 degrees from the first position. The stabilizing system may include one or more conduits for transferring a material between the first and second sections of the article rotator so that material will stabilize the article rotator at the section in which the material is positioned to prevent the article rotator from inadvertently rotating. The material of the stabilizing system may be transferred by gravity and the material of the stabilizing system may be a fluid. | 07-02-2009 |
20120292798 | Method of Rotating Mold or Other Articles - A mold rotator with a first section and a second section that are engaged approximately perpendicularly to each other to produce a base and an L-shaped platform for receiving the article. The base of the article rotator may have a curved section at the intersection of the first section and the second section and the article rotator may rotate on its curved section between a first position wherein the article rotator is supported on its first section and a second position wherein the article rotator is supported on its second section. Further, the article rotator allows an article to be safely rotated simply by lowering the article onto the article rotator so that the article rotator automatically rotates approximately 90° from a first position and a second, rotated position. The article rotator may include a stabilizing system. | 11-22-2012 |
20130291317 | Adjustable Last - An adjustable last that may be inserted into an article includes provisions so that the position of an adjustable portion of the adjustable last can be changed according to the size of the article. In some embodiments, the adjustable last includes an inflatable member that can be filled with fluid according to the size of the article, and may be used to adjust the size of the article. Other embodiments do not include an inflatable member. The adjustable last can include an adjustment assembly for adjusting the adjustable portion. The adjustment assembly can include a wedge member. | 11-07-2013 |
Patent application number | Description | Published |
20080319425 | DRUG-ELUTING GRAFT - Embodiments of the present invention provide a device for the local delivery of a substance into a natural tissue conduit in the mammalian body, having a first element capable of contacting the lumen of the conduit and a second element which overlays first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit such that a substance placed in the reservoir is delivered into the conduit. In embodiments, the first element may be fully or partially microporous or a separate intermediate microporous membrane may be provided. Also provided are methods of mixing or moving a drug within a reservoir using various mixing elements. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing a device in accordance with embodiments of the present invention. | 12-25-2008 |
20090324710 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor - Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. | 12-31-2009 |
20100008913 | Methods and compositions for treating platelet-related disorders - Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. | 01-14-2010 |
20100268188 | DRUG DELIVERY CUFF - Embodiments provide a drug delivery cuff including a drug reservoir. In an embodiment, an integrated drug pump may be provided. A drug delivery cuff in accordance with an embodiment may be placed around any suitable vascular graft (e.g., ePTFE) or directly around any natural tissue conduit (e.g., perivascularly), at any position along the graft/conduit or overlapping a graft and conduit, either at the time of graft surgical placement or separate therefrom. | 10-21-2010 |
20130022671 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR - Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. | 01-24-2013 |
Patent application number | Description | Published |
20100158890 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban. The present invention further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 06-24-2010 |
20110020349 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided. | 01-27-2011 |
20120276112 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 11-01-2012 |